The Food and Drug Administration has given approval to Phase 3 clinical trials of MDMA (ecstasy) for the treatment of post traumatic stress disorder (PTSD). This is the final step before the potential approval of ecstasy as a prescription drug.
The move comes after several successful Phase 2 studies of ecstasy, which included 130 PTSD patients. These were conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS). The new research will include at least 230 participants and will also be conducted by MAPS.